Literature DB >> 16177846

Atrioventricular nodal reentrant tachycardia with paroxysmal atrial fibrillation: clinical and electrophysiological features and predictors of atrial fibrillation recurrence following elimination of atrioventricular nodal reentrant tachycardia.

Basri Amasyali1, Sedat Kose, Kudret Aytemir, Ayhan Kilic, Gulumser Heper, Hurkan Kursaklioglu, Atila Iyisoy, Turgay Celik, E Bariş Kaya, Ersoy Isik.   

Abstract

INTRODUCTION: Clinical and electrophysiological characteristics of patients with atrioventricular nodal reentrant tachycardia (AVNRT) and paroxysmal atrial fibrillation (AF) have not been studied in a large patient cohort. We aimed to define the clinical features and cardiac electrophysiological characteristics of these patients, and to examine the incidence and identify predictors of AF recurrences after elimination of AVNRT. METHODS AND
RESULTS: Thirty-six patients with AVNRT and documented paroxysmal AF (Group 1) and 497 patients with AVNRT alone undergoing ablation in the same period (Group 2) were studied. There were no significant differences between groups regarding clinical features, except age, which was higher in Group 1 (p<0.001). Presence of atrial vulnerability (induction of AF lasting>30 seconds) and multiple AH jumps (>or=50 ms) before ablation were significantly more prevalent in Group 1 (p<0.001, p=0.010 respectively). During follow-up of 34 +/- 11 months, AF recurred in 10 patients (28%) in Group 1, while 2 patients in Group 2 (0.4%) developed paroxysmal AF (p<0.001). Univariate predictors of AF were: left atrial diameter>40 mm (p=0.001), presence of mitral or aortic calcification (p=0.003), atrial vulnerability after ablation (p=0.015) and valvular disease (p=0.042). However, independent predictors of AF recurrences were left atrial diameter>40 mm (p=0.002) and the presence of atrial vulnerability after ablation (p=0.034).
CONCLUSION: In patients with both AVNRT and paroxysmal AF, the recurrence rate of AF after elimination of AVNRT is 28%. Left atrial diameter greater than 40 mm and atrial vulnerability after elimination of AVNRT are independent predictors of AF recurrences in the long term.

Entities:  

Mesh:

Year:  2005        PMID: 16177846     DOI: 10.1007/s10840-005-2225-6

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  19 in total

1.  Dependence of electrogram duration in right posteroseptal atrium and atrium-pulmonary vein junction on pacing site: mechanism and implications regarding atrioventricular nodal reentrant tachycardia and paroxysmal atrial fibrillation.

Authors:  Y J Chen; C T Tai; M H Hsieh; C F Tsai; W S Lin; S A Chen
Journal:  J Cardiovasc Electrophysiol       Date:  2000-05

2.  Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness.

Authors:  D P Zipes; M J Mihalick; G T Robbins
Journal:  Cardiovasc Res       Date:  1974-09       Impact factor: 10.787

3.  Evaluation of atrial vulnerability with transoesophageal stimulation in patients with atrioventricular junctional reentrant tachycardia. Comparison with patients with ventricular pre-excitation and with normal subjects.

Authors:  D D'Este; A Pasqual; M Bertaglia; M P Meneghello; A Zanocco; P Delise; F D'Este; P Pascotto
Journal:  Eur Heart J       Date:  1995-11       Impact factor: 29.983

4.  Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia.

Authors:  M E Hamer; W E Wilkinson; W K Clair; R L Page; E A McCarthy; E L Pritchett
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

5.  Atrial conduction: effects of extrastimuli with and without atrial dysrhythmias.

Authors:  A E Buxton; H L Waxman; F E Marchlinski; M E Josephson
Journal:  Am J Cardiol       Date:  1984-10-01       Impact factor: 2.778

6.  Electrophysiological effect of volume load in isolated canine hearts.

Authors:  H Calkins; W L Maughan; D A Kass; K Sagawa; J H Levine
Journal:  Am J Physiol       Date:  1989-06

7.  Clinical usefulness of slow pathway ablation in patients with both paroxysmal atrioventricular nodal reentrant tachycardia and atrial fibrillation.

Authors:  P Delise; L Gianfranchi; N Paparella; M Brignole; C Menozzi; S Themistoclakis; R Mantovan; A Bonso; L Corò; A Vaglio; M Ragazzo; P Alboni; A Raviele
Journal:  Am J Cardiol       Date:  1997-05-15       Impact factor: 2.778

8.  Atrial fibrillation induced by atrioventricular nodal reentrant tachycardia.

Authors:  J Brugada; L Mont; M Matas; F Navarro-López
Journal:  Am J Cardiol       Date:  1997-03-01       Impact factor: 2.778

9.  Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry.

Authors:  F G Cosio; J Palacios; J M Vidal; E G Cocina; M A Gómez-Sánchez; L Tamargo
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

Review 10.  Atrioventricular nodal reentrant tachycardia: a review.

Authors:  L Elvas; S Gursoy; J Brugada; E Andries; P Brugada
Journal:  Can J Cardiol       Date:  1994-04       Impact factor: 5.223

View more
  3 in total

1.  Clinical and electrophysiological characteristics of the patients with relatively slow atrioventricular nodal reentrant tachycardia.

Authors:  Harun Evrengul; Yusuf I Alihanoglu; I Dogu Kilic; Bekir S Yildiz; Sedat Kose
Journal:  J Interv Card Electrophysiol       Date:  2014-05-06       Impact factor: 1.900

2.  Effect of pulmonary vein isolation on atrial fibrillation recurrence after ablation of paroxysmal supraventricular tachycardia in patients with high dispersion of atrial refractoriness.

Authors:  Zhen-xing Xu; Jing-quan Zhong; Bing Rong; Xin Yue; Zhao-tong Zheng; Qing Zhu; Shao-lei Yi; Jun-tao Wang; Man Li; Yun Zhang
Journal:  J Interv Card Electrophysiol       Date:  2014-09-17       Impact factor: 1.900

3.  Atrioventricular nodal reentrant tachycardia ablation with radiofrequency energy during ongoing tachycardia: is it feasible?

Authors:  Basri Amasyali; Ayhan Kilic; Kutsi Kabul; Murat Unlu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-11-17       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.